Salubris (信立泰) A+H Pre-IPO: 1H26 Results Update
Salubris is seeking an A+H listing. In this note we update the company's fundamentals and business development since our last coverage.
28 Views
Shenzhen Salubris Pharmaceuticals (SLBRS HK): Synthetic Expert Call Transcript (06 Sep 2026)
The S086 (Xinchaotuo) Commercial Execution is the Real Growth Driver: Following its May 2025 NMPA approval for primary hypertension and its...
100 Views
IPO Databook: Shenzhen Salubris Pharmaceuticals (002294 HK) - Sep 2026
A leading Chinese pharmaceutical company focused on the CKM sector, engaged in R&D, production, and sales of pharmaceuticals and medical...
114 Views
No more insights